Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment

Background: Most multiple sclerosis (MS) patients will develop walking limitations during the disease. Sustained-release oral fampridine is the only approved drug that will improve gait in a subset of MS patients. Objectives: (1) Evaluate fampridine cortical excitability effect in MS patients with g...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahdab, Rechdi, Shatila, Madiha M., Shatila, Abed Rahman, Khazen, George, Freiha, Joumana, Salem, Maher, Makhoul, Karim, El Nawar, Rody, El Nemr, Shaza, Ayache, Samar S., Riachi, Naji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956091/
https://www.ncbi.nlm.nih.gov/pubmed/31817319
http://dx.doi.org/10.3390/brainsci9120357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956091/
https://www.ncbi.nlm.nih.gov/pubmed/31817319
http://dx.doi.org/10.3390/brainsci9120357

Ejemplares similares